Quantitative analysis of in vitro combination effects of platinum analogs and etoposide against human lung cancer cells.

概要

論文の詳細を見る
Cisplatin (CDDP) has proven to be useful in combination with etoposide (ETP) in small-cell lung cancer (SCLC). Recently, platinum analogs, carboplatin (CBDCA) and 254-S, have been developed and are attractive candidates for combinations with ETP. The <I>in vitro</I> combination effcts of these platinum compounds and ETP were evaluated in a search for synergistic pairs. Fractional cytotoxicity (FC) was determined <I>in vitro</I> by colony assay using a human SCLC cell line. The median-effect plot was applied to quantify the combination effect of concurrent treatment of these drug pairs. A synergistic effect was reproducibly observed for combination of CDDP and ETP at fixed molar ratio of 1: 1. The combination effect of CBDCA and ETP (molar ratio 5: 2) was almost additive and was inferior to that of CDDP and ETP. On the contrary, for combination of 254-S and ETP (molar ratio 2: 1), antagonistic effect was observed at low concentrations, whereas marked synergism was obtained at higher concentrations. This synergistic effect was equal to the combination effect of CDDP and ETP at FC of 0.9 and even superior at a FC of more than 0.9. These data suggested the efficacy of 254-S in the treatment of SCLC.
特定非営利活動法人日本肺癌学会の論文